Insider Buying Continues Amid a Flat‑Market Landscape DENTSPLY SIRONA INC (XRAY) filed a Form 4/A on June 12, 2026, reporting that director Jonathan Jay Mazelsky purchased 10 000 shares at $10.14. The transaction was corrected from a prior “A” code to “P,” confirming it was a standard open‑market purchase rather than a private deal. The trade represents only 0.06 % of the company’s total shares outstanding, yet it is part of a steady stream of buying by Mazelsky that has left him holding roughly 61 700 shares—more than 1 % of the company.
What the Buying Pattern Signals Mazelsky’s purchase history over the past 18 months shows a consistent trend of buying both common stock and phantom‑stock awards. In June alone, he added 10 000 common shares and, earlier in March, bought 2 644 phantom shares at $11.34. The purchases have been largely at market price with only slight premiums (the June trade was $0.03 above the closing price). This pattern suggests a “confidence‑in‑the‑business” stance rather than a speculative play. Investors often view repeated purchases by senior directors as a positive signal that those with the most information are willing to stake more capital on the company’s future.
How It Fits Into Broader Insider Activity The June 2026 filing also shows several other senior executives, including CEO Daniel Scavilla and EVP Denti Aldo Roberto, acquiring phantom‑stock awards and common shares. The overall insider buying has been steady, with no large sales to offset it. In a market where DENTSPLY’s stock has fallen 32 % year‑to‑year and its P/E is negative, this insider optimism can help temper bearish narratives. However, the stock’s recent weekly gain of 1.68 % and a 5.85 % monthly rise are modest compared with peers, indicating that broader market forces and the company’s own earnings dynamics still weigh heavily.
Implications for Investors For shareholders, Mazelsky’s continued purchases reinforce a view that the company’s long‑term fundamentals—its global dental‑equipment platform and steady cash flow—are solid. The stock’s current price of $10.03 sits above its 52‑week low but far from its 52‑week high, offering a potential entry point for value‑oriented investors. Yet the negative earnings ratio and the company’s sensitivity to the dental‑practice cycle mean that price momentum may lag. Investors should monitor upcoming earnings releases, R&D pipeline updates, and any regulatory developments that could impact the dental‑care sector.
A Snapshot of Jonathan Jay Mazelsky Mazelsky is a non‑executive director with a background in strategic finance and corporate governance. His transaction history shows a mix of common‑stock purchases and phantom‑stock awards tied to performance metrics. Notably, he has frequently purchased phantom shares at prices around $12, indicating a willingness to invest in performance‑linked equity that matures over time. His holding growth—from about 28 000 shares in January 2026 to over 61 000 by mid‑June—reflects a deliberate accumulation strategy rather than short‑term speculation. This profile aligns with the typical profile of directors who view their equity stake as both a commitment to the company and a long‑term investment vehicle.
Bottom Line Mazelsky’s latest purchase is a small but meaningful signal that senior insiders remain bullish on DENTSPLY SIRONA. While the stock’s recent performance has been modest and its valuation metrics remain weak, the steady insider buying could provide a stabilizing influence. For investors, the move underscores the importance of assessing insider activity alongside fundamental metrics and market sentiment when evaluating a stock that operates in a cyclical, yet essential, healthcare niche.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-06-12 | MAZELSKY JONATHAN JAY () | Buy | 10,000.00 | 10.14 | Common Stock |
